European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.
Halfdan SorbyeEnrique GrandeMarianne PavelMargot TesselaarNicola FazioNicholas Simon ReedUlrich KniggeEmanuel ChristValentina AmbrosiniAnne CouvelardEva Tiensuu JansonPublished in: Journal of neuroendocrinology (2023)
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. Prognosis is generally poor for digestive NEC, most are advanced at diagnosis and median survival in metastatic disease is 11-12 months. Surgery can be of benefit for localized disease after extensive preoperative imaging. Carboplatin in combination with etoposide is recommended as first-line treatment for metastatic disease. Irinotecan with fluoropyrimidines has the best evidence as second-line treatment. Immunotherapy plays a minor role in biomarker-unselected patients. Molecular profiling if available is encouraged to identify new targets. More prospective clinical trials are highly needed to fulfil the unmet needs in this field, especially on new predictive and prognostic biomarkers and to improve survival of patients with advanced disease.
Keyphrases
- end stage renal disease
- clinical trial
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- small cell lung cancer
- healthcare
- peritoneal dialysis
- type diabetes
- minimally invasive
- high resolution
- randomized controlled trial
- quality improvement
- acute coronary syndrome
- adipose tissue
- metabolic syndrome
- coronary artery disease
- photodynamic therapy
- study protocol
- combination therapy
- free survival
- rectal cancer
- phase ii
- double blind
- percutaneous coronary intervention